ForPatients
by Roche

Systemic Lupus Erythematosus

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Trial Status	Trial Runs In	Trial Identifier
Recruiting	6 Countries	NCT07629583 2025-522904-26-00,2025 GA46280

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT07629583 2025-522904-26-00,2025 GA46280
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years & <= 75 Years	No

© 2022 F. Hoffmann-La Roche Ltd